Purpose In this study, the methylation status of RASSF1A in synovial sarcomas and the effect of demethylation on synovial sarcoma were examined. Methods The methylation status in 74 soft tissue sarcomas (STSs) including 21 synovial sarcomas was determined by methylation specific PCR. The effect of the de-methylating agent 5-aza-2 0 -deoxycytidine (5-Aza-dC) on synovial sarcoma was examined using synovial sarcoma cell lines (SYO-1 and HS-SY-II).
Introduction
Synovial sarcoma is a rare malignancy which mainly occurs in adolescents and young adults. Synovial sarcoma is considered to be a high-grade malignancy with a high risk of lung metastasis. It is estimated that approximately 40-50% of the patients develop lung metastasis (Ferrari et al. 2004) . Despite improved knowledge and treatment, more than 25% of the patients with localized disease and most of the patients with metastatic disease at diagnosis die of the disease (Eilber et al. 2007; Ferrari et al. 2004; Lewis et al. 2000) . Synovial sarcoma is characterized by the specific chromosomal translocation t(X;18)(p11.2;q11.2) which results in an SYT-SSX fusion gene (Clark et al. 1994) .
Although the SYT-SSX fusion gene is thought to play a most important role in the tumorigenicity of synovial sarcoma, the precise mechanism is not fully understood (dos Santos et al. 2001) . Recently, SYT-SSX was reported to induce epigenetic modification, including DNA methylation (de Bruijn et al. 2006 (de Bruijn et al. , 2007 . DNA methylation is major alterations during development of human cancers and methylation of promoter CpG islands is the main gene silencing mechanism of some tumor suppressor genes including the Ras association domain family 1A (RASSF1A) (Donninger et al. 2007; Herman and Baylin 2003) .
A previous study reported a loss of RASSF1 located at 3p21.3 in 6 of 13 synovial sarcoma specimens in an analysis of microarray comparative genomic hybridization (array CGH) (Nakagawa et al. 2006) . Pazzaglia et al. (2006) also reported the loss of 3p21.3-p23 region in their array-CGH analysis of 15 monophasic synovial sarcomas with low expression of RASSF1A protein. RASSF1 encodes two major transcripts, RASSF1A and RASSF1C, by alternative splicing. RASSF1A is now recognized as a tumor suppressor gene which controls cell cycle, promotes apoptosis and reduces the tumorigenicity of cancer cell lines (Agathanggelou et al. 2005; Donninger et al. 2007) . RASSF1A is frequently inactivated by promoter CpG island methylation rather than mutation or deletion in many types of cancer (Agathanggelou et al. 2005; Donninger et al. 2007; Pfeifer and Dammann 2005) . Although there are numerous reports demonstrating RASSF1A methylation in human cancers, there have been only two reports that highlighted the promoter methylation of RASSF1A in soft tissue sarcomas (STSs) (Kawaguchi et al. 2005; Seidel et al. 2005) . Moreover, a methylation analysis of RASSF1A was performed in only six cases of synovial sarcoma (Seidel et al. 2005) . The reported overall methylation rates of RASSF1A in STS are similar in these two reports, 20 and 26%, respectively. However, each methylation rate was different in some histological types. Kawaguchi et al. reported relatively frequent methylation in malignant fibrous histiocytomas (MFHs) (31%) and low methylation rate (18%) in malignant peripheral nerve sheath tumors (MPNSTs), whereas Seidel et al. reported low methylation rate (6%) in MFHs and frequent methylation in MPNSTs (50%). The methylation rate of RASSF1A in STS, particularly in synovial sarcoma, is yet to be exactly confirmed because of the small number of samples in those reports. Moreover, the effect of the promoter methylation of RASSF1A in STS is also yet to be verified.
In this study, a methylation specific PCR (MSP) analysis of RASSF1A was conducted in 74 STSs including 21 synovial sarcomas and the results were compared with the previous two reports to confirm the methylation rate of RASSF1A in STS, particularly in synovial sarcoma. In addition, de-methylation analysis using a synovial sarcoma cell line was conducted to investigate the role of RASSF1A promoter methylation in synovial sarcomas. The effect of the de-methylation agent, 5-aza-2 0 -deoxycytidine (5-AzadC), on the synovial sarcoma cell line was examined both in vitro and in vivo. These results suggest the therapeutic potential of 5-Aza-dC for the treatment of synovial sarcoma.
Materials and methods

Tissues and cell lines
The present study included 74 STS specimens (26 MFHs, 21 synovial sarcomas, 11 liposarcomas, 8 MPNSTs and 8 leiomyosarcomas) from 74 patients surgically treated at Okayama University Hospital (Okayama, Japan). In 21 synovial sarcomas, nine were monophasic subtype and 12 were biphasic subtype. SYT-SSX fusion gene was detected by RT-PCR as described in a previous paper (Naito et al. 2000) . Informed consent was obtained from all patients for experimental use of the specimens. Surgically obtained tissues were immediately frozen and stored at -80°C until analysis. Two synovial sarcoma cell lines (SYO-1, HS-SY-II) were used in this study. HS-SY-II was provided by Dr. Hiroshi Sonobe (Chugoku Central Hospital, Fukuyama, Japan). The culture conditions for those cells are described elsewhere (Kawai et al. 2004; Sonobe et al. 1992 ).
Methylation specific PCR (MSP) analysis of RASSF1A DNA was extracted using QIAamp DNA Mini Kit (QIA-GEN, Hilden, Germany) according to the manufacturer's protocol. Bisulfite modification was performed using CpGenome DNA Modification Kit (Intergen Co., Purchase, NY). Briefly, 1.0 lg of DNA was denatured by NaOH for 10 min at 37°C. 30 ll of 10 mM hydroquinone and 520 ll of 3 M sodium bisulfite were added and mixed. Samples were incubated under mineral oil at 50°C for 16 h. Bisulfite-modified DNA was amplified by PCR using primers specific for the methylated sequence and unmethylated sequence of RASSF1A promoter, as reported by Burbee et al. (2001) . The optimized thermal profile included initial denaturation at 95°C for 5 min, followed by 35 cycles of 95°C for 45 s, 64°C (for the detection of methylated DNA) or 59°C (for the detection of unmethylated DNA) for 45 s and 72°C for 45 s and a final extension at 72°C for 5 min. Negative controls without DNA were performed for each set of PCR. Each PCR product was stained with ethidium bromide separated by electrophoresis on an agarose gel and visualized under UV illumination.
De-methylation analysis using a synovial sarcoma cell line To assess the relationship between promoter methylation and the expression of RASSF1A, SYO-1 cells were treated with 5-Aza-dC. SYO-1 cells were cultured for 24, 48 and 72 h in the presence of 10 lM 5-Aza-dC. After the extraction of RNA and DNA, MSP and real-time RT-PCR was performed. RNA extraction was performed using IS-OGEN (NIPPON GENE, Tokyo, Japan). DNA extraction and MSP was performed in the same way as described above.
Quantitative real-time RT-PCR
The primers for RASSF1A (forward primer: 5 0 CCTGCA GTGCGCGCATT 3 0 , reverse primer: 5 0 ACAGGCTCGT CCACGTTC 3 0 ) were designed in order to specifically amplify the spliced forms of RASSF1A based on their splicing sites with the assistance of Primer3 primer design online software. A primer set for GAPDH (forward primer: CATCAAGAAGGTGGTGAAGCAG, reverse primer: CGTCAAAGGTGGAGGAGTGG) was used as an internal control. After reverse transcription using QuantiTect Ò Reverse Transcription Kit (QIAGEN), real-time RT-PCR was conducted using LightCycler TM (Roche Molecular Biochemicals, version 1.5). The serial dilution of the cDNA derived from healthy male leukocytes was prepared in order to make standard curves. Each reaction was performed in a total volume of 10 ll containing 1 ll of cDNA, 0.25 ll of primers (20 lM) and 2 ll of Light-cycler DNA Master SYBR Green I mix (Roche Diagnostics, Basel, Switzerland). For a negative control, PCR grade water was added instead of cDNA. After the denaturation step at 95°C for 10 min, the amplification was performed for 45 cycles at 95°C for 5 s, 68°C for 5 s and 72°C for 10 s, followed by detection at the specified acquisition temperature for 1 s. An amplification melting curve analysis was performed after the program run. Correct PCR products were confirmed by agarose gel electrophoresis and melting curve analysis.
Fluorescence immunocytochemistry
For immunofluorescence microscopy, SYO-1 cells were cultured on eight well chamber slides with or without 10 lM 5-Aza-dC for 72 h. Cells were fixed with 1% paraformaldehyde (PFA) and washed with phosphate buffer saline (PBS). SYO-1 cells were permeabilized with 0.2% Triton X-100 and fixed with 4% PFA. The cells were then incubated with 1% bovine serum albumin (BSA) in PBS to block nonspecific labeling. Subsequently, the cells were incubated for 16 h with anti-RASSF1A monoclonal antibodies (eBioscience, Inc., San Diego, CA). Cells were washed and then incubated simultaneously with Alexa 488-conjugated goat anti-mouse secondary antibody (Invitrogen, Eugene, OR) and Alexa 568-conjugated phalloidin (Invitrogen) in 0.1% BSA/PBS for 1 h. Images were acquired with SenSys0401E (Roper Scientific Germany, Ottobrunn, Germany), DMRA2 (Leica Microsystems, Wetzlar, Germany) and Leica Cytogenetic Workstation (CW4000; Leica Microsystems Imaging Ltd, Cambridge, UK).
MTT assay
MTT assay was performed using two synovial sarcoma cell lines (SYO-1 and HS-SY-II). The cells were split into 96-well plates (10 3 cells per well and four wells per each experimental condition) and cultured for 24 h before the treatment. 5-Aza-dC was dissolved in distilled water and added for culture medium as final concentrations of 0, 0.1, 1, 10 and 100 lM. After exposure to 5-Aza-dC for 48, 72 and 96 h, cell viability was determined using the MTT assay (Chemicon International Inc., Temecula, CA).
Tumor growth assay in vivo
Animals were treated according to the animal experimental guidelines of Okayama University. Eighteen mice (BALB/c nu/nu) were inoculated subcutaneously with the SYO-1 cells (1.0 9 10 6 cells per mouse). After the subcutaneous tumors developed (*5 mm in diameter), mice were divided into three groups; 1 and 10 mg/kg 5-Aza-dC treatment group and vehicle control. 5-Aza-dC or PBS (for vehicle control) was intraperitoneally injected twice a week, five times in total. Two perpendicular diameters of the tumors were measured twice a week and approximations of the tumor volumes were calculated by the following formula: tumor volume = longer diameter 9 shorter diameter 2 /2.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5 for Windows (GraphPad Software inc., CA USA). Correlation between the RASSF1A methylation status and histological type was examined by Fisher's exact test. For the in vivo tumor growth assay, the relationship between the tumor growth and 5-Aza-dC treatment was examined by two-way repeated measures ANOVA with Bonferroni as the post test. Two-tailed P values of less than 0.05 were considered to be significant.
Results
RASSF1A methylation in STS
The methylation status of RASSF1A promoter was determined by MSP in 74 STSs and two synovial sarcoma cell lines. A methylated band was detected in 20 of 74 STSs and two synovial sarcoma cell lines (Fig. 1) . The promoter methylation rates of RASSF1A were 62.5% (5/8) in MPNST, 47.6% (10/21) in synovial sarcoma, 36.4% (4/11) in liposarcoma, 12.5% (1/8) in leiomyosarcoma and 0% (0/26) in MFH ( Table 1 ). The RASSF1A methylation rate in synovial sarcoma was significantly higher than that in the other STSs (P = 0.0295). In synovial sarcoma, the methylation of RASSF1A promoter was rather frequent in monophasic subtype (6 of 9) than biphasic subtype (4 of 12) although there were no significant deference (P = 0.198). SYT-SSX1 and SYT-SSX2 were detected in 14 and 7 synovial sarcomas, respectively. RASSF1A methylation was relatively more frequent in synovial sarcoma with SYT-SSX1 (8 of 14) than that with SYT-SSX2 (2 of 7) (P = 0.361). Although this study included only eight MPNSTs, the RASSF1A methylation rate in MPNST was also significantly higher than that in the other STSs (P = 0.0194). On the other hand, the RASSF1A methylation rate of MFH was significantly lower (P \ 0.0001).
De-methylation analysis
To assess the correlation between promoter methylation and mRNA expression of RASSF1A in synovial sarcoma, an MSP and real-time RT-PCR analysis of RASSF1A were performed using SYO-1 cells treated with or without 5-Aza-dC. The methylation status of RASSF1A of SYO-1 was modified from methylated to unmethylated by the 5-Aza-dC treatment (Fig. 2a) . Unmethylated DNA of RASSF1A was detected 24 h after the 5-Aza-dC treatment. RASSF1A mRNA expression was absent in the untreated SYO-1 cells; however, after 5-Aza-dC exposure, RASSF1A mRNA expression level was increased with progress of time (Fig. 2b) . We also examined protein expression of RASSF1A by FICC. RASSF1A protein expression was induced at peri-nuclear zone of the SYO-1 cells 72 h after the 5-Aza-dC exposure (Fig. 3) . These results suggest that the expression of RASSF1A is downregulated by promoter Fig. 2 De-methylation analysis in vitro using a synovial sarcoma cell line (SYO-1). a Methylation status of RASSF1A before and after 5-Aza-dC treatment in SYO-1 determined using MSP. Unmethylated RASSF1A was detected 24 h after 5-Aza-dC exposure and seemed to reach a maximum at 48 h. M methylated products and U unmethylated products of RASSF1A. b Effect of 5-Aza-dC treatment on RASSF1A mRNA expression analyzed by duplicated real-time RT-PCR. The columns indicate the mean RASSF1A expression levels normalized to GAPDH expression methylation in SYO-1 cells and it is reversible by the treatment with de-methylation agent.
Anti-tumor effect of 5-Aza-dC treatment in vitro
The anti-tumor effect of 5-Aza-dC against synovial sarcoma was assessed by MTT assay. Estimated cell viability of SYO-1 cells with 5-Aza-dC treatment at the concentration of 0.1, 1, 10 and 100 lM were 136, 96, 71 and 64% at 48 h, 107, 84, 45 and 34% at 72 h and 78, 49, 27 and 15% at 96 h, respectively (Fig. 4) , and those of HS-SY-II were 112, 108, 114 and 109% at 48 h, 101, 85, 84 and 82% at 72 h and 90, 53, 28 and 23% at 96 h, respectively (Fig. 5) . The anti-tumor effects of 5-Aza-dC against synovial sarcoma cells were observed in a time and a dosedependent manner. The calculated IC 50 for the treatment of the SYO-1 cells were 7.7 (72 h of exposure) and 0.9 lM (96 h of exposure). The calculated IC50 for the treatment of HS-SY-II was 1.3 lM (96 h of exposure).
Effect of 5-Aza-dC treatment in vivo
The anti-tumor effect of 5-Aza-dC was confirmed in vivo using the SYO-1 xenograft model in nude mice. The growth of the xenograft tumor was significantly suppressed with 5-Aza-dC treatment analyzed with two-way repeated measures ANOVA (P \ 0.0001). The tumor volumes were significantly smaller in the 5-Aza-dC treatment groups after day 14 (P \ 0.01; Fig. 6 ). 10 mg/ kg 5-Aza-dC treatment was significantly more effective than 1 mg/kg treatment and the difference in the tumor volumes was significant at days 21 and 24. Tumor growth after the final administration of 5-Aza-dC seemed to be slower in the 5-Aza-dC treatment groups. The mRNA expression level of RASSF1A was examined in the xenograft tumors. The expression levels of RASSF1A mRNA with 1 and 10 mg/kg 5-Aza-dC treatment reached 11 and 26 times those of the control group, respectively. The body weights of the mice were measured twice a week to check the toxicity of 5-Aza-dC. Although gradual weight gain was observed in all the three groups, a relatively greater increase in weight of the control mice, compared with the 5-Aza-dC treatment mice (1 and 10 mg/kg), was observed after day 17 (data not shown). It might suggest the toxicity of 5-Aza-dC. However, the growth of the xenografted tumors might have affected the body weight gain of the control mice because the mice in the control group appeared to be thinner than the 5-AzadC treatment mice and their xenografted tumors were grown to a huge size (Fig. 6c) . The thinness in the control mice might be due to the possible invasion of their xenografted tumor into retroperitoneal space and visceral organs as reported previously (Ito et al. 2005 ).
Discussion
RASSF1A is a recently recognized tumor suppresser gene which is located at 3p21.3 within a common area of heterozygous deletions in human cancers (Dammann et al. 2000) . RASSF1A can regulate the microtubule network (van der Weyden et al. 2005) , cell cycle progression (Shivakumar et al. 2002) , and apoptosis (Oh et al. 2006) . Rassf1a knockout mice are prone to tumorigenesis, both for spontaneous tumor formation and for chemical carcinogeninduced tumor formation (Tommasi et al. 2005 ). These data demonstrate the function of RASSF1A as a tumor suppressor. Although a mutation of RASSF1A is a rare event, gene silencing of RASSF1A by promoter hypermethylation is rather frequent in human cancers (Agathanggelou et al. 2005; Donninger et al. 2007; Pfeifer and Dammann 2005) . A methylation rate of 80% or higher is reported in small cell lung cancer, breast cancer, prostate cancer, neuroblastoma and medulloblastoma (Donninger et al. 2007 ). The current study identified the RASSF1A methylation in 20 of 74 STSs (26.7%). The overall methylation rate of STSs was similar to those in the previous two reports (26 and 20%, respectively) (Kawaguchi et al. 2005; Seidel et al. 2005) . Promoter methylation of RASSF1A in STS is a relatively infrequent event in comparison with other human cancers. However, the current study showed significantly frequent methylation of RASSF1A in MPNST (62.5%) and synovial sarcoma (47.5%). Methylation of RASSF1A may not be associated with tumorigenesis in all STSs but it is in those two histological types. With a hierarchical clustering analysis using cDNA microarray data, synovial sarcoma and MPNST were grouped into the same category and shared expression patterns of numerous genes relating to neural differentiation (Nagayama et al. 2002) . Since frequent promoter methylation of RASSF1A is also reported in other neurogenic tumors such as gliomas (Lorente et al. 2008) , neuroblastomas (Lazcoz et al. 2006 ) and medulloblastomas (Lusher et al. 2002) , RASSF1A may play an important role in tumorigenesity of neurogenic malignancies.
A significant correlation between RASSF1A promoter methylation and poor survival of the patients with STS was reported by Seidel et al. (Seidel et al. 2005) . On the other hand, Kawaguchi et al. (2005) found no such a correlation, whereas they reported that the RASSF1A methylation was relatively frequent in advanced stages, based on the American Joint Committee on Cancer. In the current study, RASSF1A methylation did not affect the overall survival of the STS patients (data not shown). The methylation rate of RASSF1A was the highest in synovial sarcomas (Table 1) . A previous study reported the frequent loss of RASSF1A detected by array CGH analysis in synovial sarcoma (Nakagawa et al. 2006) . Pazzaglia et al. (2006) also reported loss of RASSF1 locus by array CGH. In their report, in spite of higher mRNA expression of RASSF1A in synovial sarcoma than that of normal tissues, the protein expression in synovial sarcoma was low to absent. They assumed that RASSF1A expression might be suppressed by post-transcriptional regulation in synovial sarcoma. However, RASSF1A is downregulated mainly by methylation of promoter CpG islands in the majority of cancers and post-transcriptional regulation of RASSF1A has not been reported previously. The current study showed frequent methylation of RASSF1A in the clinical samples of synovial sarcoma and re-expression of the RASSF1A by demethylation of its promoter in the SYO-1 synovial sarcoma cell line. These results suggest the importance of promoter methylation in the silencing of RASSF1A in synovial sarcoma.
5-Aza-dC is a DNA methyltransferase inhibitor, which causes hypomethylation of DNA and re-expression of genes which are downregulated by promoter CpG islands hypermethylation. The anti-tumor activity of 5-Aza-dC is confirmed preclinically in some neoplasm, especially in hematological malignancies (Goffin and Eisenhauer 2002; Kantarjian et al. 2007) . In contrast to the effects on acute myeloid leukemia cells, significantly fewer changes in gene expression and cytotoxicities were detected in normal peripheral blood mononuclear cells and bone marrow cells or transformed epithelial cells treated with 5-Aza-dC (Schmelz et al. 2005) . The toxicity to mice produced by intravenous injection of the 20 mg/kg dose of 5-Aza-dC was reported to be minimal as indicated by less than 3% loss in body weight (Lemaire et al. 2008) . 5-Aza-dC achieved a good clinical response in myelodysplastic syndrome (Kantarjian et al. 2007; Ruter et al. 2007 ). In the clinical trial, although frequent grade 3-4 hematologic toxicities and rare grade 3-4 toxicities of bone aches (5%) and liver dysfunction (4%) were reported, they were not fatal (Kantarjian et al. 2007) . These data support the potential of 5-Aza-dC as a candidate anti-cancer drug. However, the effect of 5-Aza-dC was yet to be verified in synovial sarcoma. In this study, MTT assay using two synovial sarcoma cell lines and tumor growth assay using the SYO-1 xenograft model in nude mice were performed. By the treatment with 5-Aza-dC, the growth of synovial sarcoma cell lines was suppressed in vitro in a dose and time dependent manner. In addition, the anti-tumor effects of 5-Aza-dC were demonstrated in vivo using the SYO-1 xenograft model in nude mice. This is the first report that identified growth suppression of synovial sarcoma by 5-Aza-dC both in vitro and in vivo. 5-Aza-dC may also be beneficial for the treatment of synovial sarcoma. Clinical trials for the treatment of solid tumors, in which STS was not included, were also performed previously (Goffin and Eisenhauer 2002) . However, they could not achieve any favorable results. A longer exposure may be necessary for the treatment of solid tumors in comparison to hematologic malignancies, because solid tumors in general have long cell cycle times (Momparler 2005 ). In the current study, the effect of different concentration and different exposing time of 5-Aza-dC on the growth of the synovial sarcoma cells was examined using the MTT assay. The results showed that long exposure (96 h) at low dose was more effective than short exposure (48 h) at high dose. The calculated IC50 of 5-Aza-dC against the SYO-1 cells were 7.7 lM for 72 h and 0.9 lM for 96 h of exposure. Zhang et al. (2007) reported even lower response rate in human breast cancer. In their report, the growth suppression rates of human breast cancer cell line treated with 5 lM 5-AzadC were 35.42% (5 days) and 71.29% (8 days). According to these studies, continuous treatment with 5-Aza-dC for more than 96 h may improve the clinical response in solid tumors. However, it is difficult to perform long term continuous administration in clinical use due to the chemical instability of 5-Aza-dC (van Groeningen et al. 1986 ). Another way to increase the anti-neoplastic activity of 5-Aza-dC is dose intensification (Lemaire et al. 2008) . With dose intensification of 5-Aza-dC, the growth of the SYO-1 xenograft tumor was significantly suppressed in our study. These data suggest that repeated administration of the drug at a relatively higher dose may be an alternative for clinical trials.
The anti-tumor effects of 5-Aza-dC against synovial sarcoma cell lines were analyzed with de-methylation and re-expression of RASSF1A in this study. Our data suggest that the growth suppression effect of 5-Aza-dC may result from de-methylation and reactivation of RASSF1A. However, as 5-Aza-dC can cause a whole genome hypomethylation, there might be any other target genes for the 5-Aza-dC treatment. There are only a few reports about promoter methylation of cancer suppresser genes in synovial sarcoma (Saito et al. 2004; Seidel et al. 2005) , and there are no other genes which have been shown to be methylated as frequently as RASSF1A. The analysis of methylation by array-based analysis of genomic DNA methylation patterns may be helpful for understanding the precise mechanisms of the drug.
Recently, SYT-SSX, the specific fusion gene transcript of synovial sarcoma, was reported to induce epigenetic gene regulation (de Bruijn et al. 2006 (de Bruijn et al. , 2007 Ito et al. 2004; Lubieniecka et al. 2008 ). de Bruijin et al. (2007 reported that induction of SYT-SSX induced genome-wide DNA methylation. They also reported that methylation at the single locus in the IGF2 imprinting control region resulted in overexpression of IGF2. Although they did not refer to promoter methylation of tumor suppressor genes such as RASSF1A, the frequent methylation of RASSF1A in synovial sarcoma observed in the current study suggests that SYT-SSX might also induce promoter methylation of RASSF1A to repress the suppressor mechanism. Epigenetic gene regulation is one of the tumorigenic mechanisms of synovial sarcoma and its modulation with de-methylation agent may be a principled approach for the treatment of synovial sarcoma.
This study showed a significantly high RASSF1A methylation rate (47.6%) in synovial sarcoma in comparison to other STSs (P = 0.0295). De-methylation analysis using the synovial sarcoma cell line revealed that RASSF1A was downregulated by promoter methylation in synovial sarcoma. Furthermore, 5-Aza-dC had an anti-tumor effect in a synovial sarcoma cell line. This is the first report to identify an anti-tumor effect of 5-Aza-dC in synovial sarcoma both in vitro and in vivo.
